Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium.
| Title: | Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium. |
|---|---|
| Authors: | Aldasoro M; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Jorda A; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Aldasoro C; Hospital General de Castellon, Castellon, Spain.; Marchio P; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Guerra-Ojeda S; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Gimeno-Raga M; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Mauricio MD; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Iradi A; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Obrador E; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Vila JM; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain.; Valles SL; Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain. |
| Source: | International journal of medical sciences [Int J Med Sci] 2017 Feb 23; Vol. 14 (3), pp. 224-230. Date of Electronic Publication: 2017 Feb 23 (Print Publication: 2017). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101213954 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-1907 (Electronic) Linking ISSN: 14491907 NLM ISO Abbreviation: Int J Med Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Australia] : Ivyspring International Publisher, c2004- |
| MeSH Terms: | Androstanols/*administration & dosage ; Neurons/*drug effects ; Vecuronium Bromide/*administration & dosage ; gamma-Cyclodextrins/*administration & dosage; Androstanols/adverse effects ; Apoptosis Inducing Factor/biosynthesis ; Caspase 3/biosynthesis ; Cytochromes c/biosynthesis ; Gene Expression Regulation/drug effects ; Neuromuscular Blocking Agents/administration & dosage ; Neuromuscular Blocking Agents/adverse effects ; gamma-Cyclodextrins/adverse effects ; Animals ; Dose-Response Relationship, Drug ; Drug Combinations ; Humans ; Primary Cell Culture ; Rats ; Rocuronium ; Sugammadex |
| Abstract: | Rocuronium (ROC) and Vecuronium (VEC) are the most currently used steroidal non-depolarizing neuromuscular blocking (MNB) agents. Sugammadex (SUG) rapidly reverses steroidal NMB agents after anaesthesia. The present study was conducted in order to evaluate neuronal effects of SUG alone and in combination with both ROC and VEC. Using MTT, CASP-3 activity and Western-blot we determined the toxicity of SUG, ROC or VEC in neurons in primary culture. SUG induces apoptosis/necrosis in neurons in primary culture and increases cytochrome C (CytC), apoptosis-inducing factor (AIF), Smac/Diablo and Caspase 3 (CASP-3) protein expression. Our results also demonstrated that both ROC and VEC prevent these SUG effects. The protective role of both ROC and VEC could be explained by the fact that SUG encapsulates NMB drugs. In BBB impaired conditions it would be desirable to control SUG doses to prevent the excess of free SUG in plasma that may induce neuronal damage. A balance between SUG, ROC or VEC would be necessary to prevent the risk of cell damage. |
| Competing Interests: | Competing Interests: The authors have declared that no competing interest exists. |
| References: | Int J Med Sci. 2013 Aug 03;10(10):1278-85. (PMID: 23983586); Anaesthesia. 2011 Jun;66(6):526-7. (PMID: 21568994); Biopharm Drug Dispos. 2011 Apr;32(3):159-67. (PMID: 21370235); Rev Bras Anestesiol. 2012 Jul;62(4):538-42. (PMID: 22793969); J Crit Care. 2009 Mar;24(1):29-35. (PMID: 19272536); Paediatr Anaesth. 2016 Jan;26(1):109-11. (PMID: 26456087); Br J Anaesth. 2008 Mar;100(3):373-9. (PMID: 18238834); Anesthesiology. 1994 May;80(5):1155-61; discussion 29A. (PMID: 7912481); J Clin Anesth. 2009 Sep;21(6):444-53. (PMID: 19833281); J Anesth. 2016 Apr;30(2):290-7. (PMID: 26646837); Anesthesiology. 2007 Feb;106(2):283-8. (PMID: 17264722); Drugs. 2009;69(7):919-42. (PMID: 19441874); Anaesthesia. 2009 Mar;64 Suppl 1:10-21. (PMID: 19222427); Eur J Anaesthesiol. 2015 Oct;32(10):681-6. (PMID: 26225497); Anaesth Intensive Care. 2014 Jan;42(1):93-6. (PMID: 24471669); Br J Anaesth. 2012 Sep;109(3):382-90. (PMID: 22732111); Br J Anaesth. 2000 Nov;85(5):717-23. (PMID: 11094587); Br J Anaesth. 2004 Mar;92(3):419-21. (PMID: 14742342); Allergol Int. 2016 Jan;65(1):52-5. (PMID: 26666489); Anesthesiology. 1997 Nov;87(5):1096-105. (PMID: 9366462); Basic Clin Pharmacol Toxicol. 2016 Jun;118(6):462-7. (PMID: 26505986); J Investig Allergol Clin Immunol. 2012;22(5):382. (PMID: 23101320); J Med Chem. 2002 Apr 25;45(9):1806-16. (PMID: 11960492); Acta Pharmacol Sin. 2011 Dec;32(12):1454-9. (PMID: 21986576); Expert Opin Pharmacother. 2016;17 (6):819-33. (PMID: 26799963); BMC Anesthesiol. 2010 Sep 01;10:15. (PMID: 20809967); Anal Biochem. 1977 Dec;83(2):346-56. (PMID: 603028); J Immunol Methods. 1983 Dec 16;65(1-2):55-63. (PMID: 6606682); Br J Anaesth. 2004 Aug;93(2):241-8. (PMID: 15169739); Mol Vis. 2000 Dec 31;6:287-93. (PMID: 11141572); Anesthesiology. 2014 Nov;121(5):969-77. (PMID: 25208233); Anesth Analg. 2007 Mar;104(3):575-81. (PMID: 17312211); Am J Ther. 2009 Jul-Aug;16(4):295-9. (PMID: 19535969); Can J Anaesth. 1996 Jun;43(6):617-20. (PMID: 8773869); Anaesthesia. 2012 Oct;67(10):1101-4. (PMID: 22827538); Anesthesiol Clin. 2010 Dec;28(4):691-708. (PMID: 21074746); Br J Anaesth. 2000 Nov;85(5):763-78. (PMID: 11094595); Br J Pharmacol. 2006 Jan;147 Suppl 1:S277-86. (PMID: 16402115); Acta Anaesthesiol Scand. 2002 Nov;46(10):1236-41. (PMID: 12421196); Presse Med. 2016 Sep;45(9):768-73. (PMID: 27234905); J Cereb Blood Flow Metab. 2013 Jun;33(6):898-905. (PMID: 23462571); Anesthesiology. 2011 Feb;114(2):318-29. (PMID: 21239968); Anesthesiology. 2008 Nov;109(5):816-24. (PMID: 18946293); Anaesthesia. 2009 Mar;64 Suppl 1:1-9. (PMID: 19222426); J Anal Toxicol. 2008 Jul-Aug;32(6):422-7. (PMID: 18652748); Anaesth Intensive Care. 2014 Jan;42(1):89-92. (PMID: 24471668); Br J Anaesth. 2011 Dec;107 Suppl 1:i60-71. (PMID: 22156271); Anesth Essays Res. 2013 Sep-Dec;7(3):302-6. (PMID: 25885973); Anaesth Intensive Care. 2016 May;44(3):425-7. (PMID: 27246945) |
| Contributed Indexing: | Keywords: apoptosis.; neuron; rocuronium; sugammadex; vecuronium |
| Substance Nomenclature: | 0 (Aifm1 protein, rat); 0 (Androstanols); 0 (Apoptosis Inducing Factor); 0 (Drug Combinations); 0 (Neuromuscular Blocking Agents); 0 (gamma-Cyclodextrins); 361LPM2T56 (Sugammadex); 7E4PHP5N1D (Vecuronium Bromide); 9007-43-6 (Cytochromes c); EC 3.4.22.- (Caspase 3); WRE554RFEZ (Rocuronium) |
| Entry Date(s): | Date Created: 20170404 Date Completed: 20170717 Latest Revision: 20200528 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC5370284 |
| DOI: | 10.7150/ijms.17545 |
| PMID: | 28367082 |
| Database: | MEDLINE |
Journal Article